RAMM Pharma Corp. RAMM
CNSX
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -71.04% | -77.07% | -78.42% | -41.64% | -27.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -71.04% | -77.07% | -78.42% | -41.64% | -27.13% |
| Cost of Revenue | -72.59% | -90.75% | -90.02% | -73.89% | 49.94% |
| Gross Profit | 3,300.00% | -13.27% | -37.48% | -10.74% | -99.93% |
| SG&A Expenses | 2.01% | -0.36% | -23.69% | -56.20% | -42.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 33.33% | -44.23% | -70.27% | -35.80% | -26.67% |
| Total Operating Expenses | -33.88% | -38.16% | -47.20% | -57.59% | -17.92% |
| Operating Income | -0.71% | -1.58% | 21.38% | 61.76% | 6.98% |
| Income Before Tax | -66.96% | -152.82% | 30.08% | 38.72% | 47.54% |
| Income Tax Expenses | -- | -- | -- | 30.51% | -- |
| Earnings from Continuing Operations | -66.96% | -38.45% | 23.97% | 38.67% | 47.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.96% | -38.45% | 23.97% | 38.67% | 47.54% |
| EBIT | -0.71% | -1.58% | 21.38% | 61.76% | 6.98% |
| EBITDA | -6.22% | -23.67% | 12.98% | 63.93% | -11.86% |
| EPS Basic | -65.63% | -41.67% | 23.33% | 38.64% | 47.54% |
| Normalized Basic EPS | -61.90% | 52.17% | 9.76% | 34.67% | 44.74% |
| EPS Diluted | -65.63% | -41.67% | 23.33% | 38.64% | 47.54% |
| Normalized Diluted EPS | -61.90% | 52.17% | 9.76% | 34.67% | 44.74% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |